Reported results
- GAAP Net Loss of $5.6 million and GAAP Diluted EPS of ($0.06) for the quarter.
- Adjusted Net Income of $4.3 million and Adjusted Diluted EPS of $0.04 for the quarter.
- Total Company Adjusted EBITDA of $3.9 million for the quarter.
- Operated Segment Adjusted EBITDA of $9.1 million for the quarter.
- Total cash, cash equivalents, equity securities measured at fair value and loans receivable of $346.3 million, or $3.55 per share.
Notes
Investment securities representing equity method investments decreased to zero at September 30, 2026, compared to $19.9 million at December 31, 2025, as a result of the impairment of the Company’s investment in MalinJ1 during the second quarter of 2026.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.
